Peroxiredoxin 6 (PRDX6) is a bifunctional enzyme comprising a peroxidase and a Ca2+-independent phospholipase (iPLA2) activity. This renders the enzyme capable of detoxifying reactive oxygen species (ROS) and of catalyzing the liberation of arachidonic acid (AA) from cellular membranes. Released AA can be further metabolized to bioactive lipids including eicosanoids, which are involved in inflammation, cell growth, differentiation, invasion and proliferation. Human melanoma cells are often characterized by imbalances in both ROS and lipid levels, which can be generated by oncogenic signaling, altered metabolism or UV irradiation. In previous studies, a comparative proteome analysis of the Xiphophorus fish melanoma model revealed a strong upregulation of Prdx6 in benign and malignant lesions compared to healthy skin. As the Xiphophorus melanoma model displays in many respects molecular characteristics that are similar to human melanoma, I investigated the functional role of PRDX6 in human melanoma cells. The first part of the study deals with the regulation of PRDX6 in melanocytes and human melanoma cells. I could demonstrate that the protein level of PRDX6 was strongly enhanced by the induction of the EGFR orthologue Xmrk from the Xiphophorus fish as well as the human EGFR. The upregulation of PRDX6 was further shown to be mediated in a PI3K-dependent and ROS-independent manner. The main part of the thesis comprises the investigation of the functional role of PRDX6 in human melanoma cells as well as the analysis of the underlying mechanism. I could show that knockdown of PRDX6 enhanced the oxidative stress response and led to decreased proliferation of melanoma cells. This cell growth effect was mainly mediated by the iPLA2 activity of PRDX6. Under conditions of strongly enhanced oxidative stress, the peroxidase activity became also important for cellular proliferation. Furthermore, the anti-proliferative effect in cells with lowered PRDX6 levels was the result of reduced cellular AA content and the decrease in the activation of SRC family proteins. Similarly, supplementation with AA led to regeneration of SRC family kinase activity and to an improvement in the reduced proliferation after knockdown of PRDX6. Since AA can be further processed into the prostaglandin PGE2, which has a pro-tumorigenic function in some cancer types, I further examined whether this eicosanoid is involved in the proliferative function of PRDX6. In contrast to AA, PGE2 was not consistently required for melanoma proliferation. In summary, I could demonstrate that PRDX6 plays a major role in AA-dependent lipid signaling in melanoma cells and thereby regulates proliferation. Interestingly, the proliferation relevant iPLA2 activity can be pharmacologically targeted, and melanoma cell growth was clearly blocked by the inhibitor BEL. Thus, I could identify the phospholipase activity of PRDX6 as a new therapeutically interesting target for melanoma treatment. / Peroxiredoxin 6 (PRDX6) ist ein bifunktionales Enzym, welches neben seiner Peroxidase-Aktivität auch eine Ca2+-unabhängige Phospholipase-Aktivität besitzt. Aufgrund dieser beiden Aktivitäten ist das Enzym in der Lage, sowohl oxidativen Stress zu bekämpfen als auch die Freisetzung von Arachidonsäure aus zellulären Membranen zu katalysieren. Freie Arachidonsäure (AA) dient der Generierung von bioaktiven Lipiden wie zum Beispiel Eicosanoiden, welche an Entzündungsreaktionen, Zellwachstum, Differenzierung, Invasion und Proliferation beteiligt sind. Humane Melanomzellen zeichnen sich oft durch ein gestörtes Gleichgewicht reaktiver Sauerstoffspezies und zellulärer Lipide aus. Dieses Ungleichgewicht kann durch onkogene Signalgebung, einen veränderten Metabolismus oder UV-Bestrahlung hervorgerufen werden. Eine vorangegangene Proteomanalyse des Xiphophorus-Fisch-Melanommodells zeigte, dass im Vergleich zur gesunden Haut die Menge an PRDX6 in benignen und malignen Läsionen stark erhöht ist. Da das Xiphophorus-Melanommodell in vielerlei Hinsicht die molekulare Situation des humanen Melanoms wiederspiegelt, habe ich die funktionale Rolle von PRDX6 in humanen Melanomzellen untersucht. Der erste Teil der Studie beschäftigt sich mit der Regulierung von PRDX6 in Melanozyten und humanen Melanomzellen. Ich konnte nachweisen, dass die Menge an PRDX6 Protein durch die Induktion des EGFR Orthologs Xmrk aus Xiphophorus Fischen, sowie des humanen EGFR stark erhöht wurde. Auch konnte ich zeigen, dass die Heraufregulierung von PRDX6 von der Signalgebung der PI3 Kinase, aber nicht von reaktiven Sauerstoffspezies abhängig war. Der Hauptteil der vorliegenden Forschungsarbeit befasst sich mit der Ermittlung der funktionalen Rolle von PRDX6 in humanen Melanomzellen und der Analyse des zugrundeliegenden Mechanismus. Ich konnte nachweisen, dass ein Knockdown von PRDX6 die oxidative Stress-Antwort verstärkte und die Proliferation von Melanomzellen reduzierte. Der Effekt auf das zelluläre Wachstum wurde hierbei hauptsächlich durch die iPLA2-Aktivität von PRDX6 verursacht. Bei stark erhöhtem oxidativem Stress konnte auch eine Relevanz der Peroxidase-Aktivität für die zelluläre Proliferation nachgewiesen werden. Auch ging der anti-proliferative Effekt mit einer Abnahme zellulärer AA und der Reduktion aktiver Kinasen der SRC-Familie einher. Die Zugabe von AA zu Zellen mit PRDX6-Knockdown führte zur Regeneration der SRC-Kinase-Aktivität und konnte die Proliferation wieder verbessern. Da AA zum Prostaglandin PGE2 prozessiert werden kann, welches in einigen Krebsarten pro-tumorigene Funktionen erfüllt, untersuchte ich, ob dieses Eicosanoid auch für die proliferative Funktion von PRDX6 relevant ist. Im Gegensatz zu AA wies PGE2 jedoch keine kontinuierliche pro-proliferative Funktion auf. Zusammenfassend konnte ich zeigen, dass PRDX6 eine entscheidende Rolle im AA- Stoffwechsel von Melanomzellen spielt und hierdurch die Proliferation reguliert. Interessanterweise ist die proliferationsrelevante iPLA2-Aktivität pharmakologisch hemmbar, und auch das Wachstum der Melanomzellen wurde durch den Inhibitor BEL deutlich inhibiert. Mit der Phospholipase-Aktivität von PRDX6 konnte ich somit einen neuen therapeutisch nutzbaren Angriffspunkt für das Melanom identifizieren.

共著者あり。共著者名: Kuniaki Suzuki, Masatake Yoshikawa, Tohru Imai, Akira Matsumotob and Shinji Nakamura. Elsevier Science Ltd., Takashi Kajii, Kuniaki Suzuki, Masatake Yoshikawa, Tohru Imai, Akira Matsumotob and Shinji Nakamura, Long-term effects of prostaglandin E2 on the mineralization of a clonal osteoblastic cell line (MC3T3-E1), Archives of Oral Biology, 44(3), 1999 MAR, pp.233-241. doi:10.1016/S0003-9969(98)00120-4. Journal Website: http://intl.elsevierhealth.com/journals/arob/ / Prostaglandin (PG) E2 is thought to be a mediator of the effect of mechanical stress on bone formation, but its effects on osteoblasts have not yet been fully described. Here, the effects of the continuous application of PGE2 and indomethacin, an inhibitor of prostaglandin G/H synthase (cyclo-oxygenase), on the proliferation, differentiation and mineralization of a clonal osteoblastic cell line, MC3T3-E1, were investigated. The cells were cultured in media with either a high (1 μg/ml) or a low (1 ng/ml) concentration of PGE2, with indomethacin (1 μg/ml) and, as a control, with neither agent. The effects of PGE2 and indomethacin were assessed quantitatively. Indomethacin and a high concentration of PGE2 increased the total protein compared to the control and low-PGE2 cultures. 7 days after confluence, alkaline phosphatase (ALP) activity within the cells and extracellular matrices increased. This increase was highest with indomethacin and lowest with a high concentration of PGE2. ALP activity also increased in the medium, but only 21 days after confluence; the effects of the agents were similar to those on the cells and matrices. The accumulation of calcium, inorganic phosphate and hydroxyproline was highest with indomethacin. PGE2 production was at its maximum when the cells were at confluence and was inhibited by indomethacin. Specific [3H]PGE2 binding to the microsomal fraction of the cell was also measured to examine the expression of the PGE2 receptor. The amount of [3H]PGE2 binding per mg of protein was highest at confluence, then decreased and again increased in the mineralizing stage. These results suggest that indomethacin increases ALP activity and the accumulation of mineralized tissue in MC3T3-E1 cells, presumably by inhibiting the production of PGE2. PGE2 could signal the suppression of mineralization as early as confluence. / Hokkaido University (北海道大学) / 博士 / 歯学

Universiẗat, Diss.--Jena, 2008.

Konstanz, Univ., Diss., 2008.

Dissertation (Ph.D.).--University of Texas Graduate School of Biomedical Sciences at San Antonio, 2008. / Vita. Includes bibliographical references.

A new prostaglandin - prostaglandin X (later renamed prostacyclin or prostaglandin I₂ (PGI₂)), was discovered by Moncada, Gryglewski, Bunting and Vane in 1976. This unstable substance was shown to be produced by vascular tissue and to be a vasodilator and the most potent endogenous inhibitor of platelet aggregation known. Because of its properties, it appeared that a lack of it may be related to the development and or maintenance of hypertension, a disorder featuring vasoconstriction and an increased tendency to arterial thrombosis. The present studies aimed to investigate this possibility using a rat model. A bioassay for prostacyclin was first perfected. This consisted of a modification of the method used by Moncada, Higgs and Vane (1977): PGI₂ released by rat aortic strips, during incubation in tris buffer, was measured by assessing the ability of the incubate to inhibit adenosine diphosphate induced aggregation of human platelets, as compared to the inhibitory effect of standard prostacyclin sodium salt. The specificity of the assay for the detection of PGI₂ was tested. The abil ity of hypertensive rat aorta to release prostacycl in was investigated in two studies. The first compared aortas of Wistar rats of the New Zealand genetically hypertensive strain (GH) with those of matched normotensive Wistar controls. In the second study, hypertension was induced by wrappi ng the ri ght kidney with surgical silk and removing the contralateral kidney. Ten weeks later, aortic generation of prostacyclin by these animals was compared with that of matched sham controls which had received identical surgical manipulation but for the application of silk to the right kidney. Contrary to expectation, in both forms of hypertension, aortas of the rats with elevated pressure produced consistently more prostacyclin than those of matched controls. In order to discover more about the relationship between elevated pressure and elevated PGI₂ production, the effect of pressure reduction with hypotensive agents on the ability of GH rat aortas to produce prostacyclin, was investigated. After pressure had been controlled within normal range for one week (achieved by oral administration of furosemide, dihydralazine and reserpine for one month), aortic PGI₂ was reduced in comparison with matched GH controls. However, the reduction was not consistent and statistical significance was not reached. Because it was subsequently reported by other workers, that some of the hypotensive agents which had been employed may effect prostaglandin levels per se, no conclusions could be drawn from this study as to any possible direct relationships between pressure and aortic prostacyclin generating capacity. A further means of reducing elevated pressure (which had no inherent effect on prostaglandin levels) was thus sought. A mechanical method was eventually selected, application of a silver clip to the aortas of GH rats, just below the diaphragm, producing an immediate reduction in pressure distal to the constriction. Eighteen hours with later, PGI₂ production by these distal aortas those of matched sham GH controls and was was compared found to be consistently reduced. These results indicate that the ability to produce PGI₂ may be influenced by prior local pressure changes and that the increased capacity of hypertensive rat aortas to generate prostacyclin may be related to the increased mechanical transmural stress consequent on elevated pressure. Since haemostatic balance must be influenced not only by vascular PGI₂ generation but also by platelet sensitivity to PGI₂, the response of GH platelets to the anti-aggregatory effect of prostacyc1in was also investigated. As it had been shown by Sinzinger, Si1berbauer, Horsch and Gall (1981) that intra-arterial infusion of PGI₂ in humans decreased platelet sensitivity to the substance, the possibility existed that platelet sensitivity in hypertension might be reduced. This hypothesis was, however, invalidated as the sensitivity of GH platelets to the anti-aggregatory effect of PGI₂ was almost identical to that of normotensive controls. The shortcomings of the methodology and the possible importance of these findings in the hypertensive animal are discussed. The idea that elevated PGI₂ in hypertension may play a protective role both with respect to platelet aggregation and in attenuating further pressure rises is considered. It is finally suggested that it will be possible to draw more accurate conclusions as to the meaning of the increased PGI₂ generation in hypertension (both in relation to vascular tone and platelet function) only when details of production of, and sensitivity to, thromboxane A₂ are known. Thromboxane A₂ (TXA₂) is a vasoconstrictor and promotor of aggregation (Hamberg, Svensson and Samuelson, 1975) and it may be that, despite elevated vascular PGI₂ generation, the TXA₂/PGI₂ balance is still tipped in favour of vasoconstriction and platelet aggregation in hypertension.

Chronic kidney disease is defined as the appearance of kidney functional or structural injury. Cyclooxygenase and prostaglandin E2 have been implicated in the pathogenesis of diabetic nephropathy, the leading cause of chronic kidney disease. Beneficial in certain settings, inhibition of the cyclooxygenase pathway can however be detrimental in patients with compromised cardiac or renal function. Moreover, the quest for new therapies to treat diabetic nephropathy is hampered by the lack of appropriate rodent models. This doctoral thesis is a culmination of three studies, the first to determine the role of the prostaglandin E2 EP1 receptor in diabetic nephropathy, the second to elucidate the vascular prostaglandin E2 EP4 receptor’s role in hypertension and lastly to establish and characterise a novel mouse model of diabetic nephropathy. The goal being to uncover new therapeutic avenues for the treatment of CKD, its causes and/or complications.

Renal hypertrophy occurs early in the natural history of human and experimental diabetes and may be a manifestation of the same pathophysiological process which ultimately results in diabetic nephropathy. The precise biological events which stimulate and regulate this growth process remain incompletely understood. We postulated that renal eicosanoids contribute to the development of renal hypertrophy in diabetes. We elected to test the effects of suppression of dienoic eicosanoid metabolism (arachidonic acid metabolism) on renal hypertrophy in diabetic rats by feeding fish oil. Diabetic rats fed fish oil had markedly reduced insulin requirements compared to control rats pair-fed a beef tallow-rich diet. The concentrations of prostaglandin E2, 6-keto-prostaglandin F1α, and thromboxane B2 were depressed in the renal cortex of diabetic rats fed fish oil. This alteration in eicosanoid metabolism was associated with a substantial enhancement of diabetic renal hypertrophy. These results indicate that dietary fish oil has profound effects on renal eicosanoid metabolism in experimental diabetes and that these autocoids may participate in the biological events which regulate diabetic renal hypertrophy.

Observing cows in estrus and inseminating them at the optimal time are necessary steps for effective reproductive management of a dairy herd. However, increasing herd sizes can lead to reproductive inefficiency resulting in decreased profits on dairy herds. Synchronization of estrus, through pharmacological control, has been used to improve reproductive efficiency. Systematic breeding programs provide an organized approach for administering artificial insemination (AI) at first service. Moreover, reproductive management is based on a methodical approach for the entire herd rather than for the individual cow. Seven-hundred and thirty four Holstein cows from 16 commercial dairy herds were used to conduct this study evaluating three systematic breeding protocols; 14-d PGF2a, timed AI (TAI), and GnRH-PGF2α, in comparison with an untreated control group. Eight herds relied on visual observation as their primary method for detection of estrus, and 8 herds utilized the HeatWatch® (DDx, Inc., Denver, CO) electronic estrus detection system. The average days to first postpartum AI were longer for untreated control cows when compared to the other breeding protocols. First AI conception rates did not differ among control, 14-d PGF2a, or GnRH-PGF2a protocols, but were higher than the TAI protocol. However, first AI pregnancy rates were higher for untreated controls versus hormonally treated cows. Estrus characteristics associated with each protocol were also evaluated and no difference was detected across treatments. An economic analysis determining cost per pregnancy for each protocol when considering drug costs, and pregnancy rates, resulted in the highest cost per pregnancy for TAI followed by GnRH-PGF2a and 14-d PGF2a. These programs should be considered as tools for convenience and efficiency of estrus detection; however, reduced labor costs from less time spent on estrus detection may be offset by the cost of the drug protocols. Cost effectiveness must be calculated on an individual herd basis when deciding whether a systematic breeding program is the appropriate choice. / Master of Science

京都大学 / 0048 / 新制・課程博士 / 博士(医科学) / 甲第19629号 / 医科博第67号 / 新制||医科||5(附属図書館) / 32665 / 京都大学大学院医学研究科医科学専攻 / (主査)教授 椛島 健治, 教授 岩井 一宏, 教授 渡邊 直樹 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM